2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionMode of deathEjection fractionCause-specific deathHeart failureCardiovascular deathNew York Heart Association class IIGuideline-directed medical therapyStudy case report formsSudden deathVentricular ejection fractionRate of sudden deathAssociated with lower ratesCox regression modelsImproved ejection fractionRandomized clinical trialsReduce cardiovascular mortalityCase report formsEnd-point committeeClinical end point committeePost Hoc AnalysisDapagliflozin EvaluationIV symptomsHFimpEFMedical therapy
2021
Sudden cardiac death after acute decompensation in heart failure patients: implications of discharge haemoglobin levels
Fukuoka R, Kohsaka S, Shiraishi Y, Sawano M, Abe T, Levy W, Nagatomo Y, Nishihata Y, Goda A, Kohno T, Kawamura A, Fukuda K, Yoshikawa T. Sudden cardiac death after acute decompensation in heart failure patients: implications of discharge haemoglobin levels. ESC Heart Failure 2021, 8: 3917-3928. PMID: 34323007, PMCID: PMC8497203, DOI: 10.1002/ehf2.13414.Peer-Reviewed Original ResearchConceptsSudden cardiac deathPump failure deathAcute HF patientsDischarge Hb levelsHeart failure patientsMode of deathHb levelsHF patientsFailure patientsCardiac deathEjection fractionHemoglobin levelsIncidence of SCDConsecutive acute HF patientsSeattle Proportional Risk ModelDischarge hemoglobin levelsProspective multicentre registryBaseline ejection fractionMean Hb levelNon-cardiovascular causesSeverity of anemiaSCD risk predictionProportional risk modelFailure deathHF management
2014
Risk Factors for Major Adverse Events Late after Fontan Palliation
Elder RW, McCabe NM, Veledar E, Kogon BE, Jokhadar M, Rodriguez FH, McConnell ME, Book WM. Risk Factors for Major Adverse Events Late after Fontan Palliation. Congenital Heart Disease 2014, 10: 159-168. PMID: 25130602, PMCID: PMC4512755, DOI: 10.1111/chd.12212.Peer-Reviewed Original ResearchConceptsMajor adverse eventsAdult Fontan patientsAdverse eventsRisk factorsFontan patientsFontan palliationOxygen desaturationPortal hypertensionVentricular functionAdverse outcomesTransplant-free survival rateLate-term outcomesSystemic oxygen desaturationSystolic ventricular functionAdverse event profileCongestive heart failureKaplan-Meier methodTertiary academic centerAdditional risk factorsImportant risk factorMode of deathFontan failureFontan typeSystemic ventricleThromboembolic events
2013
The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results
Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ, Investigators S. The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results. JACC Heart Failure 2013, 1: 400-408. PMID: 24621972, PMCID: PMC3829618, DOI: 10.1016/j.jchf.2013.04.012.Peer-Reviewed Original ResearchConceptsMode of deathIschemic cardiomyopathy patientsMedical therapySTICH trialMyocardial infarction deathsCABG therapyCardiomyopathy patientsSudden deathProspective clinical trial dataAddition of CABGStrategy of CABGCoronary artery bypassReduced ejection fractionClinical events committeeClinical trial dataPre-specified definitionsCABG patientsArtery bypassCardiovascular deathNoncardiovascular deathEjection fractionHeart failureEvents committeeProtective effectCABG
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply